Enterprise_Boruida Biotechnology | Focused on Biological Therapy

86-027-5931-8269

Language

English

Chinese

BLOG INFORMATION

Home page

Enterprise

Industry

Media

2024-08

The kick-off meeting of the BRD-01 phase II clinical trial of Porida biological cell therapy drug was successfully held.

2024-08-08

2024-08

Good news! Polida Biology Selected in 2023 "Science and Technology China" New Enterprise List

2024-08-08

2024-01

Porita Bio's First Cell Therapy Drug BRD-01 Recognized by FDA Orphan Drug Qualification

2024-01-31

2023-12

Porida Biologics Statement on FDA's Investigation into CAR-T Cell Therapy May Trigger T-Cell Secondary Tumors

Recently, the company was concerned about the U.S. FDA's announcement on November 28, 2023, on individual reports of T-cell tumors in patients receiving targeted BCMA or CD19 autologous CAR-T cell immunotherapy. The FDA said, "While the overall benefits of the approved uses of these products continue to exceed their potential risks, the FDA is evaluating the need for regulatory action1."

2023-12-01

Porida Biologics Statement on FDA's Investigation into CAR-T Cell Therapy May Trigger T-Cell Secondary Tumors

2023-03

CAR-T major good! National Institute for Health and Clinical Excellence (NICE) approves NHS regular use of CAR-T for diffuse large B- cell lymphoma

2023-03-03

2023-03

Quick questions, quick answers! This article takes you to read CAR-T cell therapy.

In recent years, with the continuous progress of cell therapy technology, the word CAR-T has begun to appear frequently in the public eye, and the news of the 1.2 million of an anti-cancer drug is still fresh in the memory of many friends. For ordinary cancer patients and families, the launch of CAR-T products is both gratifying and worrying. On the one hand, it is the hope of survival, and on the other hand, it is the "sky-high price" that countless people cannot afford 』.

2023-03-03

Quick questions, quick answers! This article takes you to read CAR-T cell therapy.

2022-09

Polida Biotechnology Won the Top 100 List of China's Pharmaceutical Innovation Seed Enterprises in 2022

2022-09-14

2022-05

[Information] | Hubei Daily: Major Breakthrough in Treatment of Solid Tumors by CAR-T Cell Technology in Han

2022-05-16

2022-05

Polida Biological Health Weekly (No. 89)

2022-05-09

2022-05

Polida Biological Health Weekly (No. 90)

2022-05-09

< 1 >

86-027-59318269

Official E-mail: cart@bio-raid.com

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Official WeChat

Company address: Floor 4 and Floor 5 (1) of Building 3, Phase 3.1, Wuhan Optics Valley International Biomedical Enterprise Accelerator, 388 Gaoxin 2nd Road, Donghu New Technology Development Zone, Wuhan City

Mail：cart@bio-raid.com

Telephone：86-027-59318269

WhatsApp：86-027-59318269